Wingate Wealth Advisors’s CorMedix CRMD Stock Holding History

Wingate Wealth Advisors’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.01M	Hold	128,502	–	–	0.44%	49
2026 Q1	$873K	Hold	128,502	–	–	0.47%	51
2025 Q4	$1.49M	Sell	128,502 -1,035	-0.8%	-$11.4K	0.83%	36
2025 Q3	$1.51M	Hold	129,537	–	–	1.04%	32
2025 Q2	$1.6M	Buy	129,537 +3,522	+3%	+$38.9K	1.42%	24
2025 Q1	$776K	Hold	126,015	–	–	0.89%	41
2024 Q4	$1.02M	Buy	+126,015	New	+$1.26M	1%	28

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Wingate Wealth Advisors's CRMD Position: Q2 2026 in Review

Wingate Wealth Advisors held its CorMedix (CRMD) position steady in Q2 2026 at 128,502 shares worth $1.01M. The position accounts for 0.44% of the portfolio, ranked #49.

Wingate Wealth Advisors first reported a position in CRMD in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.6M in Q2 2025. 194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

Wingate Wealth Advisors held 128,502 shares of CorMedix worth $1.01M as of Q2 2026.
Wingate Wealth Advisors left its CorMedix share count unchanged in Q2 2026.
CorMedix made up 0.44% of Wingate Wealth Advisors's portfolio in Q2 2026, its #49 holding.
Wingate Wealth Advisors first reported a position in CorMedix in Q4 2024 and has held it in 7 quarters since.
Wingate Wealth Advisors's CorMedix position peaked at $1.6M in Q2 2025.
194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Wingate Wealth Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.